204 related articles for article (PubMed ID: 18635971)
1. Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase.
Di Vizio D; Adam RM; Kim J; Kim R; Sotgia F; Williams T; Demichelis F; Solomon KR; Loda M; Rubin MA; Lisanti MP; Freeman MR
Cell Cycle; 2008 Jul; 7(14):2257-67. PubMed ID: 18635971
[TBL] [Abstract][Full Text] [Related]
2. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression.
Di Vizio D; Sotgia F; Williams TM; Hassan GS; Capozza F; Frank PG; Pestell RG; Loda M; Freeman MR; Lisanti MP
Cancer Biol Ther; 2007 Aug; 6(8):1263-8. PubMed ID: 17786030
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.
Karantanos T; Karanika S; Wang J; Yang G; Dobashi M; Park S; Ren C; Li L; Basourakos SP; Hoang A; Efstathiou E; Wang X; Troncoso P; Titus M; Broom B; Kim J; Corn PG; Logothetis CJ; Thompson TC
Oncotarget; 2016 Jul; 7(29):46321-46334. PubMed ID: 27331874
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer.
Fiorentino M; Zadra G; Palescandolo E; Fedele G; Bailey D; Fiore C; Nguyen PL; Migita T; Zamponi R; Di Vizio D; Priolo C; Sharma C; Xie W; Hemler ME; Mucci L; Giovannucci E; Finn S; Loda M
Lab Invest; 2008 Dec; 88(12):1340-8. PubMed ID: 18838960
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome.
Witkiewicz AK; Nguyen KH; Dasgupta A; Kennedy EP; Yeo CJ; Lisanti MP; Brody JR
Cell Cycle; 2008 Oct; 7(19):3021-5. PubMed ID: 18802406
[TBL] [Abstract][Full Text] [Related]
6. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth.
Gang X; Yang Y; Zhong J; Jiang K; Pan Y; Karnes RJ; Zhang J; Xu W; Wang G; Huang H
Oncotarget; 2016 Mar; 7(12):15135-49. PubMed ID: 26934656
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine phosphorylation of caveolin-2 at residue 27: differences in the spatial and temporal behavior of phospho-Cav-2 (pY19 and pY27).
Wang XB; Lee H; Capozza F; Marmon S; Sotgia F; Brooks JW; Campos-Gonzalez R; Lisanti MP
Biochemistry; 2004 Nov; 43(43):13694-706. PubMed ID: 15504032
[TBL] [Abstract][Full Text] [Related]
8. Diet-induced obesity increases melanoma progression: involvement of Cav-1 and FASN.
Pandey V; Vijayakumar MV; Ajay AK; Malvi P; Bhat MK
Int J Cancer; 2012 Feb; 130(3):497-508. PubMed ID: 21387314
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-1 Regulates the P2Y2 Receptor Signaling in Human 1321N1 Astrocytoma Cells.
Martinez NA; Ayala AM; Martinez M; Martinez-Rivera FJ; Miranda JD; Silva WI
J Biol Chem; 2016 Jun; 291(23):12208-22. PubMed ID: 27129210
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression.
Ventura R; Mordec K; Waszczuk J; Wang Z; Lai J; Fridlib M; Buckley D; Kemble G; Heuer TS
EBioMedicine; 2015 Aug; 2(8):808-24. PubMed ID: 26425687
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation.
Coleman DT; Bigelow R; Cardelli JA
Mol Cancer Ther; 2009 Jan; 8(1):214-24. PubMed ID: 19139131
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
[TBL] [Abstract][Full Text] [Related]
13. Fatty acylated caveolin-2 is a substrate of insulin receptor tyrosine kinase for insulin receptor substrate-1-directed signaling activation.
Kwon H; Lee J; Jeong K; Jang D; Pak Y
Biochim Biophys Acta; 2015 May; 1853(5):1022-34. PubMed ID: 25667086
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
15. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.
Ayala G; Morello M; Frolov A; You S; Li R; Rosati F; Bartolucci G; Danza G; Adam RM; Thompson TC; Lisanti MP; Freeman MR; Vizio DD
J Pathol; 2013 Sep; 231(1):77-87. PubMed ID: 23729330
[TBL] [Abstract][Full Text] [Related]
16. Promotion of human mesenchymal stem cell osteogenesis by PI3-kinase/Akt signaling, and the influence of caveolin-1/cholesterol homeostasis.
Baker N; Sohn J; Tuan RS
Stem Cell Res Ther; 2015 Dec; 6():238. PubMed ID: 26626726
[TBL] [Abstract][Full Text] [Related]
17. Differential subcellular membrane recruitment of Src may specify its downstream signalling.
de Diesbach P; Medts T; Carpentier S; D'Auria L; Van Der Smissen P; Platek A; Mettlen M; Caplanusi A; van den Hove MF; Tyteca D; Courtoy PJ
Exp Cell Res; 2008 Apr; 314(7):1465-79. PubMed ID: 18316074
[TBL] [Abstract][Full Text] [Related]
18. FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma.
Chianese U; Papulino C; Ali A; Ciardiello F; Cappabianca S; Altucci L; Carafa V; Benedetti R
J Transl Med; 2023 Jan; 21(1):32. PubMed ID: 36650542
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.
Zhuang L; Kim J; Adam RM; Solomon KR; Freeman MR
J Clin Invest; 2005 Apr; 115(4):959-68. PubMed ID: 15776112
[TBL] [Abstract][Full Text] [Related]
20. Caveolin mediates rapid glucocorticoid effects and couples glucocorticoid action to the antiproliferative program.
Matthews L; Berry A; Ohanian V; Ohanian J; Garside H; Ray D
Mol Endocrinol; 2008 Jun; 22(6):1320-30. PubMed ID: 18308897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
